Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
- 8 December 2009
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 2 (100) , ra80
Abstract
Cells addicted to different oncogenic receptor tyrosine kinases develop common downstream mechanisms to sustain malignancy.Keywords
This publication has 54 references indexed in Scilit:
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasionBritish Journal of Cancer, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- A module of negative feedback regulators defines growth factor signalingNature Genetics, 2007
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003